Huntingdon Life Sciences and Harlan Laboratories announce new equity funding
Huntingdon Life Sciences (HLS) and Harlan Laboratories, soon to be called Envigo, announced that a group of institutional investors has committed up to $125 million in a minority equity financing that can be used to fund future growth initiatives.
Brian Cass, CEO, commented: “We recently announced our rebranding of the Company to Envigo as we complete the integration of HLS and Harlan to broaden the support we provide to life science research. This equity investment of up to $125 million validates the success of that integration and further strengthens the Company’s balance sheet to pursue additional organic and strategic investments. We look forward to leveraging the resources of the investor group as we continue to grow Envigo and enhance our market leading position.”
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland - €85 million investment creates greater manufacturing capacity to deliver new medicines for patients
Phylogica and Isogenica: Strategic alliance fast tracking screening of drug discovery targets
ESF EURYI award winner aims to stop cancer cells reading their own DNA
Lundbeck moves Lu AA39959 into clinical phase II for the treatment of patients with bipolar disorder
New study uncovers mechanisms underlying how diabetes damages the heart
Biocartis strengthens management team with general counsel
EDISON values SYGNIS at 37.5 million euros
Thomas Meier to become new COO of Bachem Group
